Timely screening and accurate detection through precision diagnostics, targeted therapy, risk reducing surgeries, and comprehensive multimodality treatment options have resulted in improving survival rates and quality of life in cancer patients in India
Acquisition expands Merck’s growing hematology portfolio
The laboratory is equipped to perform high-volume diagnostic testing services
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Acquisition brings leading sickle cell disease portfolio and pipeline to Pfizer with potential to address critical needs in an underserved patient community
Transformation to pure-play Innovative Medicines company nears completion
These moves are designed to strengthen the company’s medical and scientific focus and support its continued record growth through closer alignment of all aspects of strategy, sales, and delivery to delight customers
In first-line metastatic NSCLC, KEYTRUDA-based regimens have now shown a five-year survival benefit in four trials
If approved, Tafinlar + Mekinist may offer a potential new standard-of-care for pediatric patients with this brain cancer
The new Oncology CRO will aim to drive faster execution and higher quality trial outcomes for Oncology sponsors.
Subscribe To Our Newsletter & Stay Updated
